(Hypertension. 2001;37:99.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
Presented in part in abstract form at the 31st Annual Meeting of the American Society of Nephrology (J Am Soc Nephrol. 1998;9:309A), the 53rd Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research (Hypertension. 1999;34:364), and the 32nd Annual Meeting of the American Society of Nephrology (J Am Soc Nephrol. 1999;10:348A).
From the Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Correspondence to Hiroyuki Kobori, MD, PhD, Department of Physiology, SL39, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA 70112-2699. E-mail hkobori{at}tulane.edu
| Abstract |
|---|
|
|
|---|
Key Words: human renin gene expression hormones, thyroid response elements
| Introduction |
|---|
|
|
|---|
Renin and renin mRNA are expressed in many cell types, such as in the placental, ovarian, testicular,4 adrenal,5 and pituitary6 7 cells of a number of species. The expression of renin is particularly high in juxtaglomerular cells.8 Juxtaglomerular cells are difficult to isolate and culture, and they lose their ability to produce renin after a single passage.9 Thus, because of the lack of any established renin-producing cell lines, very little is known about the mechanisms that control human renin gene expression.
Recently, Lang et al10 showed that the cell line Calu-6, derived from human lung cancer, endogenously produces human renin and renin mRNA. Successive studies have demonstrated that renin synthesis in Calu-6 cells, like juxtaglomerular cells, is activated by cAMP11 and inhibited by mechanical stretch.12 Therefore, the Calu-6 cell line is a potentially useful model for studying transcriptional regulation of the human renin gene.
We recently reported that thyroid hormone directly stimulates renin mRNA in vivo13 and in vitro.14 In the present study, we examined 2 hypotheses: (1) that thyroid hormone increases renin mRNA in Calu-6 cells and (2) that thyroid hormone stimulates the promoter activity of the human renin gene in Calu-6 cells.
| Methods |
|---|
|
|
|---|
Expression of Human Thyroid Hormone Receptor-ß
Calu-6 cells were rinsed 3 times with PBS, collected by
scraping, resuspended in 500 µL guanidine isothiocyanate, and
homogenized with a Polytron homogenizer
(Kinematica) for 30 seconds at 4°C. Total RNA from cultured Calu-6
cells was extracted using a total RNA extraction kit (Clontech)
according to the manufacturers protocol.
RT-PCR was performed with the GeneAmp RNA PCR core kit (PerkinElmer Cetus). Sense (5'-GAG GAG AAG AAA TGT AAA GG-3') and antisense (5'-TGT TGC CAT GCC AAC ATA GAT GC-3') primers for PCR amplification of human thyroid hormone receptor-ß (hTR-ß) cDNA corresponded to hTR-ß gene nucleotides +250 through +269 and +491 through +513, respectively.15 PCR was performed for 30 cycles with a 30-second denaturation step at 94°C, a 60-second annealing step at 50°C, and a 75-second extension step at 72°C. The PCR product was sequenced to confirm that it was hTR-ß cDNA through dideoxy sequencing with the ABI PRISM cycle sequencing kit (PerkinElmer Cetus). The sequences obtained were identical to those previously reported.15
Expression Analysis
Total RNA from cultured Calu-6 cells was extracted as described
earlier. Quantitative RT-PCR was performed precisely as previously
described.16 17 18 Sense (5'-AAT GAA GGG GGT GTC TGT GG-3')
and antisense (5'-CAC GAC ATA ATC AAA CAG CC-3') primers for PCR
amplification of human renin cDNA corresponded to human renin gene
nucleotides +812 through +831 and +952 through +971,
respectively.19 Sense (5'-CGG ATT TGG TCG TAT TGG GC-3')
and antisense (5'-AAA TGA GCC CCA GCC TTC TCC-3') primers for PCR
amplification of human
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) cDNA
corresponded to human GAPDH gene nucleotides +87 through
+106 and +375 through +395, respectively.20 PCR was
performed for 30 cycles with a 30-second denaturation step at 94°C, a
60-second annealing step at 57°C, and a 75-second extension step at
72°C. After coamplification of total RNA with each sense and
antisense primer, gel electrophoresis exhibited 2 clear bands at 160
and 309 bp that represent the human renin and GAPDH genes,
respectively. GAPDH mRNA was used as an internal standard, because
thyroid hormone treatment did not alter the quantity of this mRNA in
Calu-6 cells. Human renin mRNA expression was determined as the ratio
of the human renin to GAPDH band density. The PCR products were
sequenced to confirm that they were human renin and human GAPDH cDNA
with the ABI PRISM cycle sequencing kit. The sequences obtained were
identical to those previously reported.19 20
Constructs
Human genomic DNA was isolated with a GenTLE kit (Takara) from
peripheral blood of a healthy volunteer. With this genomic
DNA used as a template, overlapping 5'-flanking intervals of the human
renin gene were isolated by PCR with an LA PCR kit version 2 (Takara).
Sense (5'-GCC AAG CAT TCA TTA ACC C-3') and antisense (5'-GCT GAT CGT
AAG GAC TGA ATG AC-3') primers for PCR amplification of human renin
5'-flanking area corresponded to human renin gene
nucleotides -2754 through -2736 (relative to the start
site of human gene transcription) and +226 through +248,
respectively.19 Each PCR cycle consisted of a 30-second
denaturation step at 94°C, a 60-second annealing step at 54°C, and
a 75-second extension step at 72°C, for a total of 30 cycles. The PCR
product was cloned into the pT7Blue(R) T-Vector (Novagen) to
generate the construct pT7Blue(R)+248/-2754. Fusions between the
5'-flanking overlapping intervals and the luciferase reporter gene were
made with the pGL3-Basic vector (Promega). The plasmids
pGL3-Basic-1298/+12, pGL3-Basic-1111/+12, pGL3-Basic-953/+12,
pGL3-Basic-452/+12, pGL3-Basic-226/+12, and pGL3-Basic-144/+12 have
a common 3' end at +12 and promoters of varying lengths and were cloned
as shown in Figure 1A. Sequences of all
constructs were confirmed through dideoxy sequencing with an ABI PRISM
cycle sequencing kit.
|
Transfection Studies
Plasmid DNAs were purified with a commercial kit (Qiagen).
Transient DNA transfection was performed with Tfx-20 Reagent (Promega).
The culture medium was replaced with serum-free medium shortly before
the transfection. Each luciferase reporter plasmid (0.5 µg) was
cotransfected with 0.5 µg of the pRL-TK vector (Promega). When
needed, T3 (10-7 mol/L)
was added immediately. Twenty-four hours after transfection, the cells
were lysed by the addition of 100 µL passive lysis buffer (Promega).
Luciferase activity assays were performed with the Dual Luciferase
Reporter Assay System (Promega) and were read in a TD-20/20 automatic
luminometer (Turner Designs). The pRL-TK luciferase activity was used
to correct for transfection efficiency, sample loss, and other factors
that could affect the results. Experiments in which pRL-TK luciferase
activity varied by >2-fold were discarded. Consequently, when
luciferase activities of pRL-TK were evaluated as the transfection
efficiency, the efficiency varied within 1.9-fold (maximum 59 840,
minimum 32 070, and average 45 694±1915 luminometric units). In a
preliminary study, we examined the relation between transfection time
and luciferase activity by using pGL-Basic-144/+12 without
T3. When cells were harvested 12 hours after
transfection, luciferase activity was 25 008±1124 luminometric units
(n=6). Luciferase activity significantly increased at 24 and 36 hours
(47 308±3121 and 42 206±3065 luminometric units, respectively) and
then notably decreased at 48 hours to 26 990±1039 luminometric units.
Therefore, as noted above, we harvested cells 24 hours after
transfection in the following protocols.
Mutant Study
Domain mutants were generated from pGL3-Basic-1111/+12 plasmid
with a QuickChange site-directed mutagenesis kit (Stratagene) according
to the manufacturers recommendations. Mutants-1, -2, and -3 (M1, M2,
and M3) were changed from 5'-AGG TCA-3' (-1066 to -1061) to 5'-TCA
AGG-3', from 5'-AGG TCA-3' (-1061 to -1056) to 5'-TCA AGG-3', and
from 5'-GTT CCT-3' (-1051 to -1046) to 5'-TCC TTG-3', respectively
(Figure 2A). The transfection study was
performed as described earlier.
|
Electrophoretic Mobility Shift Assays
Nuclear extracts were prepared from 108
confluent Calu-6 cells according to the Hennighausen
method.21 The -1111/-953 DNA fragment of the intact
human renin gene was 5'-end labeled with
-32P-ATP (Amersham Pharmacia Biotech) with
T4 polynucleotide kinase (Takara).
Ten micrograms of nuclear protein from Calu-6 cells or bovine serum
albumin was incubated for 30 minutes at room temperature in the
presence of 0.3 U of poly(dI/dC) in 20 mmol/L Tris-glycine (pH
7.6) and 1 mmol/L EDTA. The 5'-labeled probe (0.1 pmol) was added,
and the preparation was further incubated for 30 minutes at room
temperature. After chilling on ice, the mixture was run on an 8%
nondenaturing polyacrylamide gel and exposed for
autoradiography. In competition assays, a 200-fold
excess of unlabeled -1111/-953 DNA fragment of the intact human renin
gene or the 3 human renin gene mutants was added to the reaction
mixture and incubated for 30 minutes at room temperature before
incubation with the labeled probe.
RNase Protection Assays
The levels of hTR-ß, renin, and GAPDH mRNA were also measured
by RNase protection of specific oligonucleotide probes
using the Multi-NPA Kit (Ambion) according to the manufacturers
protocol. For hTR-ß mRNA detection, a 53-mer
oligonucleotide antisense to the hTR-ß mRNA with 10
nucleotides mismatched at its 3'-end was used. The sequence
of this oligomer is 5'-CGT GAT ACA GCG GTA GTG ATA CCC GGT GGC TTT GTC
ACC ACA Ctc tgt gta gt-3', complementary to nucleotides
+312 through +354 of the hTR-ß gene.15 To detect renin
mRNA, a 51-mer oligonucleotide complementary to the
human renin mRNA with 9 nucleotides mismatched at its
3'-ends was used. The sequence of this oligomer (5'-GGA GCT GGT AGA ACC
TGA GAT GTA GGA TGC ACC GGT GTC TAC gtg gca ttg-3') is complementary to
nucleotides +873 through +914 of the human renin
gene.19 The lowercase letters of both oligomers
represent the mismatched bases. The levels of human GAPDH mRNA
were measured in these studies with a commercially available 44-mer
(Ambion) that gives a 36-mer nuclease-protected fragment. These probes
were 5'-end labeled as described earlier. The radiolabeled probe (300
pg
4x104 cpm) was hybridized to 10 µg
of sample total RNA and subjected to nuclease treatment. The
nuclease-protected oligomers were analyzed by 15%
polyacrylamide, 7 mol/L urea gel (Novex) electrophoresis.
Statistical Analysis
Statistical analysis was performed with an unpaired
t test or 1-way ANOVA with the post hoc Schéffe
F test. All data are presented as mean±SEM.
P<0.05 was considered significant.
| Results |
|---|
|
|
|---|
|
The effect of thyroid hormone on the expression of renin mRNA is depicted in Figure 4A. According to quantitative RT-PCR, thyroid hormone significantly increased human renin mRNA levels by 92% (2.30±0.20 versus 1.20±0.10, densitometric ratio to GAPDH, Figure 4B). The enhancement of the expression of the human renin gene by thyroid hormone treatment was also confirmed with RNase protection assay (Figure 4C). Densitometric analysis showed that thyroid hormone significantly increased human renin mRNA levels by 98% (2.58±0.21 versus 1.30±0.02, densitometric ratio to GAPDH, Figure 4D).
|
The effect of varying lengths of the 5'-flanking sequence on the promoter activity of the human renin gene is shown in Figure 1B. Under basal conditions, pGL3-Basic-144/+12 showed more reporter activity than the parent pGL3-Basic plasmid (1155±219 luminometric units). Less reporter activity was observed from extracts of cells transfected with pGL3-Basic-266/+12 than from those transfected with pGL3-Basic-144/+12. pGL3-Basic-452/+12 showed more activity than pGL3-Basic-226/+12. pGL3-Basic-953/+12 demonstrated less activity than pGL3-Basic-452/+12. pGL3-Basic-1111/+12 and pGL3-Basic-1298/+12 exhibited less activity than pGL3-Basic-953/+12.
The effect of thyroid hormone on the promoter activity of the human renin gene is shown in Figure 1C. In comparison with basal activity, thyroid hormone stimulated the promoter activity of pGL3-Basic-1111/+12 and pGL3-Basic-1298/+12 by 2.3±0.1- and 1.7±0.1-fold, respectively. Other shorter constructs did not exhibit stimulation by thyroid hormone.
The effects of mutations in the putative thyroid hormone (THRE) motifs are shown in Figure 2B. Basal promoter activities were significantly increased in M1, M2, and M3 compared with pGL3-Basic-1111/+12 (lanes 2 to 4), whereas thyroid hormone did not stimulate promoter activities in mutated constructs (lanes 5 to 7).
The interaction of the putative human renin gene THRE with the nuclear proteins of Calu-6 cells was examined with electrophoretic mobility shift assay. Figure 2C shows the binding of Calu-6 cell nuclear extract with the labeled putative THRE. A single specific band appeared with retarded mobility (lane 2). No specific band was observed when the labeled DNA was incubated with bovine serum albumin alone (lane 1). Furthermore, the binding of labeled putative THRE to the nuclear proteins was displaced by the excessive unlabeled DNA fragment of the intact human renin gene (lane 3). The excessive unlabeled DNA fragments of the 3 mutants of the human renin gene did not show any obvious changes in electrophoretic mobility (lanes 4 to 6).
| Discussion |
|---|
|
|
|---|
Our results also suggested that the 5'-flanking DNA sequences, -226/-144, -953/-452, and -1111/-953, contain a negative regulatory element (Figure 1B), which is consistent with the findings of Lang et al ,10 Sun et al,22 23 and Borensztein et al.24 The 5'-flanking DNA sequence -452/-226 appears to contain a positive regulatory element (Figure 1B), which is also consistent with the findings of Sun et al.22 However, pGL3-Basic-1111/+12 and pGL3-Basic-1298/+12 repressed promoter activity (Figure 1B).
The sequences -1111/+12 and -1298/+12 had significantly increased promoter activity with thyroid hormone treatment; constructs with sequences -144/+12, -226/+12, -452/+12, and -953/+12 did not show any significant changes. These stimulatory effects of T3 on luciferase activity with constructs pGL3-Basic-1111/+12 and -1298/+12 suggest that hTR-ß bound to THRE and activated basal promoter activity in the presence of thyroid hormone. Because the shorter construct did not show any response to T3, the sequence between -1111 and -953 may contain a THRE.
We found 3 candidate THRE motifs (5'-AGG TCA-3') in sequence -1111/-953: (1) 5'-AGG TCA-3' (-1066 to -1061), (2) 5'-AGG TCA-3' (-1061 to -1056), and (3) 5'-GTT CCT-3' (-1051 to -1046). The most common motifs of THRE are an inverted palindrome without spaces (AGG TCA TGA CCT)25 and a direct repeat with 4 spaces (AGG TCA (n)4 AGG TCA).26 However, other patterns have been recently reported to be THREs.27 28 When variation in the THRE motif is taken into account, it is possible that the perfect direct repeat without space (5'-AGG TCA GGT CA-3', -1066 to -1056) and the nearly perfect inverted palindrome spaced by 4 bp (5'-AGG TCA caa tGT TCC T-3', -1061 to -1046) are putative THREs.
Nucleotides 5'-AGG TCA GGT CAc aat GTT CCT-3' (-1066 to -1046) inhibited renin gene promoter activity. It has been reported that hTR-ß constitutively binds to THRE and represses basal promoter activity in the absence of thyroid hormone. It is possible that hTR-ß could not bind the mutated THRE motif sequences in the present study and therefore could not repress basal promoter activity. In addition, the stimulatory effect of thyroid hormone was abolished by each mutation, indicating that thyroid hormone and hTR-ß cannot form a complex on the mutated THRE.
The electrophoretic mobility shift assay data (Figure 2C)
further confirmed that the intact putative THRE is important for
binding with Calu-6 cell nuclear extract and that all 3 putative motifs
are essential for the interaction of the putative THRE of the human
renin gene with Calu-6 cell nuclear proteins. This result is
consistent with the luciferase assay studies shown in Figure 2B. In Figure 2B, each mutated construct lost all thyroid
hormone responsiveness, whereas each construct had intact 2 putative
motifs. It is, however, still not clear why the remaining 2 motifs in
each mutant DNA fragment of the human renin gene, M1, M2, and M3, did
not compete with intact DNA probe. It is possible that the binding
ability of DNA with 3 intact motifs is so potent that the remaining 2
motifs in mutated DNA cannot replace the binding between wild-type DNA
and the nuclear proteins. Previous reports showed that 3 motifs worked
as 1 THRE in the
-myosin heavy chain,29 growth
hormone,30 and malic enzyme31 genes. Sugawara
et al32 examined the role of 3 THRE motifs in the growth
hormone gene and, consistent with our present data, found
that the interaction of THRE and hTR-ß was lost when 1 of 3 putative
motifs was mutated, suggesting that all 3 half-sites are necessary.
In conclusion, we present the following findings. (1) Thyroid hormone stimulated renin mRNA expression in Calu-6 cells. (2) Thyroid hormone stimulated the promoter activity of the pGL3-Basic-1111/+12 and the pGL3-Basic-1298/+12 by 2.3±0.1- and 1.7±0.1-fold over basal levels, respectively; however, other shorter constructs (pGL3-Basic-144/+12, pGL3-Basic-226/+12, pGL3-Basic-452/+12, and pGL3-Basic-953/+12) were not stimulated by thyroid hormone. (3) In sequence -1111/-953, there is a 5'-AGG TCA GGT CAc aat GTT CCT-3' sequence that may be a THRE. Mutant studies indicated that hTR-ß could not repress the basal promoter activity in the absence of thyroid hormone. (4) The intact motif of the putative THRE is important for binding to Calu-6 cell nuclear proteins. These results suggest that thyroid hormone stimulates the promoter activity of the human renin gene through a THRE-dependent mechanism in Calu-6 cells.
| Acknowledgments |
|---|
Received June 15, 2000; first decision July 10, 2000; accepted July 12, 2000.
| References |
|---|
|
|
|---|
2. Sealey JE, Quimby FW, Itskoviz J, Rbattu S. The ovarian renin-angiotensin system. Front Neuroendocrinol. 1990;11:213237.
3. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:10981104.[Abstract]
4. Sealey JE, Glorioso N, Itskovitz J, Laragh JH. Prorenin as a reproductive hormone: new form of the renin system. Am J Med. 1986;81:10411046.[Medline] [Order article via Infotrieve]
5.
Sigmund CD, Gross KW. Structure, expression, and
regulation of the murine renin genes. Hypertension. 1991;18:446457.
6.
Naruse K, Takii Y, Iagami T. Immunohistochemical
localization of renin in luteinizing hormone-producing cells of rat
pituitary. Proc Natl Acad Sci U S A. 1981;78:75797583.
7.
Deschepper CF, Mellon SH, Cumin F, Baxter JD, Ganong
WF. Analysis by immunocytochemistry and in situ hybridization
of renin and its mRNA in kidney, testis, adrenal, and pituitary of the
rat. Proc Natl Acad Sci U S A. 1986;83:75527556.
8.
Hackenthal E, Paul M, Ganten D, Tugner R. Morphology,
physiology, and molecular biology of renin secretion. Physiol
Rev. 1990;70:10671116.
9. Galen FX, Devaux C, Houot AM, Menard J, Corvol P, Corvol MT, Gubler MC, Mounier F, Camilleri JP. Renin biosynthesis by human tumoral juxtaglomerular cells: evidence for a renin precursor. J Clin Invest. 1984;73:11441155.
10.
Lang JA, Ying LH, Morris BJ, Sigmund CD.
Transcriptional and posttranscriptional mechanisms regulate human renin
gene expression in Calu-6 cells. Am J Physiol. 1996;271:F94F100.
11.
Ying L, Morris BJ, Sigmund CD. Transactivation of the
human renin promoter by the cyclic AMP/protein kinase A pathway is
mediated by both cAMP-responsive element binding protein-1
(CREB)-dependent and CREB-independent mechanisms in Calu-6 cells.
J Biol Chem. 1997;272:24122420.
12. Carey RM, McGrath HE, Pentz ES, Gomez RA, Barrett PQ. Biomechanical coupling in renin-releasing cells. J Clin Invest. 1997;100:15661574.[Medline] [Order article via Infotrieve]
13.
Kobori H, Ichihara A, Suzuki H, Miyashita Y, Hayashi M,
Sruta T. Thyroid hormone stimulates renin synthesis in rats without
involving the sympathetic nervous system. Am J Physiol. 1997;272:E227E232.
14. Ichihara A, Kobori H, Miyashita Y, Hayashi M, Sruta T. Differential effects of thyroid hormone on renin secretion, content, and mRNA in juxtaglomerular cells. Am J Physiol. 1998;274:E224E231.
15. Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ Evans RM. The c-erb-A gene encodes a thyroid hormone receptor. Nature. 1986;324:641646.[Medline] [Order article via Infotrieve]
16.
Kobori H, Ichihara A, Suzuki H, Takenaka T, Miyashita
Y, Hayashi M, Sruta T. Role of the renin-angiotensin system
in cardiac hypertrophy induced in rats by hyperthyroidism.
Am J Physiol. 1997;273:H593H599.
17. Kobori H, Ichihara A, Miyashita Y, Hayashi M, Sruta T. Mechanism of hyperthyroidism-induced renal hypertrophy in rats. J Endocrinol. 1998;159:914.[Abstract]
18. Kobori H, Ichihara A, Miyashita Y, Hayashi M, Sruta T. Local renin-angiotensin system contributes to hyperthyroidism-induced cardiac hypertrophy. J Endocrinol. 1999;160:4347.[Abstract]
19. Hardman JA, Hort YJ, Catanzaro DF, Tellam JT, Baxter JD, Morris BJ, Sine J. Primary structure of the human renin gene. DNA. 1984;3:457468.[Medline] [Order article via Infotrieve]
20.
Ercolani L, Florence B, Denaro M, Aexander M. Isolation
and complete sequence of a functional human
glyceraldehyde-3-phosphate dehydrogenase gene.
J Biol Chem. 1988;263:1533515341.
21. Hennighausen L, Lbon H. Interaction of protein with DNA in vitro. Methods Enzymol. 1987;4:429435.
22.
Sun J, Oddoux C, Lazarus A, Gilbert MT, Catanzaro DF.
Promoter activity of human renin 5'-flanking DNA sequences is
activated by the pituitary-specific transcription factor Pit-1.
J Biol Chem. 1993;268:15051508.
23.
Sun J, Oddoux C, Gilbert MT, Yan Y, Lazarus A, Campbell
WG Jr, Catanzaro DF. Pituitary-specific transcription factor (Pit-1)
binding site in the human renin gene 5'-flanking DNA stimulates
promoter activity in placental cell primary cultures and pituitary
lactosomatotropic cell lines. Circ Res. 1994;75:624629.
24.
Borensztein P, Germain S, Fuchs S, Philippe J, Corvol
P, Pnet F. cis-Regulatory elements and
trans-acting factors directing basal and cAMP-stimulated
human renin gene expression in chorionic cells. Circ Res. 1994;74:764773.
25. Glass CK, Holloway JM, Devary OV, Rosenfeld MG. The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements. Cell. 1988;54:313323.[Medline] [Order article via Infotrieve]
26. Umesono K, Murakami KK, Thompson CC, Evans RM. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell. 1991;65:12551266.[Medline] [Order article via Infotrieve]
27.
Xiong S, Chirala SS, Hsu MH, Wakil SJ. Identification
of thyroid hormone response elements in the human fatty acid synthase
promoter. Proc Natl Acad Sci U S A. 1998;95:1226012265.
28.
Zhang CY, Kim S, Harney JW, Larsen PR. Further
characterization of thyroid hormone response elements in the human type
1 iodothyronine deiodinase gene. Endocrinology. 1998;139:11561163.
29. Izumo S, Mhdavi V. Thyroid hormone receptor alpha isoforms generated by alternative splicing differentially activate myosin HC gene transcription. Nature. 1988;334:539542.[Medline] [Order article via Infotrieve]
30.
Norman MF, Lavin TN, Baxter JD, West BL. The rat growth
hormone gene contains multiple thyroid response elements. J
Biol Chem. 1989;264:1206312073.
31.
Petty KJ, Desvergne B, Mitsuhashi T, Nikodem VM.
Identification of a thyroid hormone response element in the malic
enzyme gene. J Biol Chem. 1990;265:73957400.
32. Sugawara A, Yen PM, Chin WW. 9-cis Retinoic acid regulation of rat growth hormone gene expression: potential roles of multiple nuclear hormone receptors. Endocrinology. 1994;135:19561962.[Abstract]
This article has been cited by other articles:
![]() |
V. T. Todorov, M. Desch, T. Schubert, and A. Kurtz The Pal3 Promoter Sequence Is Critical for the Regulation of Human Renin Gene Transcription by Peroxisome Proliferator-Activated Receptor-{gamma} Endocrinology, September 1, 2008; 149(9): 4647 - 4657. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kuipers, P. van der Harst, G. Navis, L. van Genne, F. Morello, W. H. van Gilst, D. J. van Veldhuisen, and R. A. de Boer Nuclear Hormone Receptors as Regulators of the Renin-Angiotensin-Aldosterone System Hypertension, June 1, 2008; 51(6): 1442 - 1448. [Full Text] [PDF] |
||||
![]() |
V. T. Todorov, M. Desch, N. Schmitt-Nilson, A. Todorova, and A. Kurtz Peroxisome Proliferator-Activated Receptor-{gamma} Is Involved in the Control of Renin Gene Expression Hypertension, November 1, 2007; 50(5): 939 - 944. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chen, L. C. Carey, N. K. Valego, and J. C. Rose Thyroid hormone replacement normalizes renal renin and angiotensin receptor expression in thyroidectomized fetal sheep Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R701 - R706. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ozawa and H. Kobori Crucial role of Rho-nuclear factor-{kappa}B axis in angiotensin II-induced renal injury Am J Physiol Renal Physiol, July 1, 2007; 293(1): F100 - F109. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ozawa, H. Kobori, Y. Suzaki, and L. G. Navar Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions Am J Physiol Renal Physiol, January 1, 2007; 292(1): F330 - F339. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chen, L. C. Carey, N. K. Valego, J. Liu, and J. C. Rose Combined Thyroidectomy and Renal Denervation Suppress Renin Expression and Secretion in Fetal Sheep Reproductive Sciences, December 1, 2006; 13(8): 604 - 609. [Abstract] [PDF] |
||||
![]() |
K. Chen, L. C. Carey, N. K. Valego, J. Liu, and J. C. Rose Thyroid hormone modulates renin and ANG II receptor expression in fetal sheep Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2005; 289(4): R1006 - R1014. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chen, L. C. Carey, J. Liu, N. K. Valego, S. B. Tatter, and J. C. Rose The effect of hypothalamo-pituitary disconnection on the renin-angiotensin system in the late-gestation fetal sheep Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2005; 288(5): R1279 - R1287. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |